{"filing":{"accession_number":"0001193125-26-290661","cik":"0000034956","ticker":"TENX","company_name":"TENAX THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"d117070d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526290661/d117070d8k.htm"},"events":[{"id":15064,"run_id":13437,"accession_number":"0001193125-26-290661","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses entry into two material definitive agreements: a Supply Agreement with Orion for manufacture and supply of the Oral Product (with a five-year initial term and automatic renewals), and a Sixth Amendment to the License Agreement extending the regulatory approval milestone to December 31, 2035. While these are contractual arrangements material to the Company's development and commercialization of its levosimendan product, they do not constitute a merger, acquisition, disposition, or change of control (ma_activity), nor do they fit other specific event categories. This is a material operational/strategic agreement that affects the Company's ability to develop and commercialize its product candidate.","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12689,"accession_number":"0001193125-26-290661","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into two material definitive agreements: a Supply Agreement with Orion for manufacture and supply of the Oral Product (with a five-year initial term and automatic renewals), and a Sixth Amendment to the License Agreement extending the regulatory approval milestone to December 31, 2035. While these are contractual arrangements material to the Company's development and commercialization of its levosimendan product, they do not constitute a merger, acquisition, disposition, or change of control (ma_activity), nor do they fit other specific event categories. This is a material operational/strategic agreement that affects the Company's ability to develop and commercialize its product candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:23:05.564075+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12689,"accession_number":"0001193125-26-290661","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into two material definitive agreements: a Supply Agreement with Orion for manufacture and supply of the Oral Product (with a five-year initial term and automatic renewals), and a Sixth Amendment to the License Agreement extending the regulatory approval milestone to December 31, 2035. While these are contractual arrangements material to the Company's development and commercialization of its levosimendan product, they do not constitute a merger, acquisition, disposition, or change of control (ma_activity), nor do they fit other specific event categories. This is a material operational/strategic agreement that affects the Company's ability to develop and commercialize its product candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:23:05.564075+00:00","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-06-30"}]}